The CEO received total reported compensation of $16,783,853 for only four months of service, primarily due to a $1.7 million cash sign-on bonus and $14.7 million in new-hire equity awards (buy-out RSUs and stock options) that were reported all at once in the summary compensation table — a level that substantially exceeds the benchmark for a CEO at a ~$1.4 billion medical device company even accounting for new-hire components. More importantly, the pay-for-performance alignment test fails: PROCEPT's stock lost 26.4% over three years while the Russell 2000 Index (^RUT — Russell 2000) gained 56.2%, an 82.6 percentage-point gap, yet above-benchmark incentive pay was awarded. Compounding this concern, the company's revenue fell below the minimum threshold in the pre-established bonus plan, yet the Compensation Committee overrode the formula and paid 80% of target — this discretionary override undermines the integrity of the performance-based pay structure and is a meaningful governance red flag.

PwC has served as PROCEPT's auditor since November 2020 (approximately five years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees of $2,000 (an online accounting research tool subscription) represent less than 0.1% of audit fees of $1,889,000, far below the 50% threshold; and PwC is a Big 4 firm appropriate for a $1.4 billion market-cap company.